These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 3542279)

  • 1. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists.
    Ashton JH; Schmitz JM; Campbell WB; Ogletree ML; Raheja S; Taylor AL; Fitzgerald C; Buja LM; Willerson JT
    Circ Res; 1986 Nov; 59(5):568-78. PubMed ID: 3542279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses.
    Ashton JH; Ogletree ML; Michel IM; Golino P; McNatt JM; Taylor AL; Raheja S; Schmitz J; Buja LM; Campbell WB
    Circulation; 1987 Oct; 76(4):952-9. PubMed ID: 3652429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries.
    Golino P; Buja LM; Ashton JH; Kulkarni P; Taylor A; Willerson JT
    Circulation; 1988 Sep; 78(3):701-11. PubMed ID: 3409505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.
    Yao SK; Ober JC; McNatt J; Benedict CR; Rosolowsky M; Anderson HV; Cui K; Maffrand JP; Campbell WB; Buja LM
    Circ Res; 1992 Jan; 70(1):39-48. PubMed ID: 1727687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists.
    Hanasaki K; Arita H
    Biochem Pharmacol; 1988 Oct; 37(20):3923-9. PubMed ID: 2973322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries.
    Bush LR; Campbell WB; Buja LM; Tilton GD; Willerson JT
    Circulation; 1984 Jun; 69(6):1161-70. PubMed ID: 6546902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
    Grover GJ; Schumacher WA; Simon M; Parham C
    J Cardiovasc Pharmacol; 1988 Dec; 12(6):701-9. PubMed ID: 2467089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe.
    Komiotis D; Wencel-Drake JD; Dieter JP; Lim CT; Le Breton GC
    Biochem Pharmacol; 1996 Sep; 52(5):763-70. PubMed ID: 8765474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin S2 and thromboxane A2-prostaglandin H2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries.
    Ashton JH; Golino P; McNatt JM; Buja LM; Willerson JT
    J Am Coll Cardiol; 1989 Mar; 13(3):755-63. PubMed ID: 2521875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis.
    Yao SK; Benedict CR; Rosolowsky M; McNatt J; Falinska B; Campbell WB; Buja LM; Willerson JT
    J Mol Cell Cardiol; 1991 Apr; 23(4):473-82. PubMed ID: 1942081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective modulation of the human platelet thromboxane A2/prostaglandin H2 receptor by eicosapentaenoic and docosahexaenoic acids in intact platelets and solubilized platelet membranes.
    Parent CA; Lagarde M; Venton DL; Le Breton GC
    J Biol Chem; 1992 Apr; 267(10):6541-7. PubMed ID: 1532390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations.
    Yao SK; Rosolowsky M; Anderson HV; Golino P; NcNatt JM; De Clerck F; Buja LM; Willerson JT
    J Am Coll Cardiol; 1990 Sep; 16(3):705-13. PubMed ID: 2143767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist-induced phosphorylation of human platelet TXA2/PGH2 receptors.
    Okwu AK; Mais DE; Halushka PV
    Biochim Biophys Acta; 1994 Mar; 1221(1):83-8. PubMed ID: 8130280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photoaffinity receptor antagonist for human platelet thromboxane A2/prostaglandin H2 receptors.
    Mais DE; Liel N; Halushka PV
    Biochem Pharmacol; 1990 Oct; 40(7):1457-61. PubMed ID: 2145838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
    Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
    J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcellular localization of a thromboxane A2/prostaglandin H2 receptor antagonist binding site in human platelets.
    Saussy DL; Mais DE; Baron DA; Pepkowitz SH; Halushka PV
    Biochem Pharmacol; 1988 Feb; 37(4):647-54. PubMed ID: 2963640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
    Mais DE; Kochel PJ; Saussy DL; Halushka PV
    Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The thromboxane A2 mimetic U46619 worsens canine myocardial hypoperfusion during exercise in the presence of a coronary artery stenosis.
    Bache RJ; Dai XZ
    Cardiovasc Res; 1992 Apr; 26(4):351-6. PubMed ID: 1638566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.